The global gout therapeutics market is expected to reach a value of USD 8.3 billion By 2025. The gout therapeutics market is anticipated to witness significant growth during the forecast period. This can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.
In December 2015, AstraZeneca's product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the U. S. FDA to treat gout. Later in February 2016, the European Commission approved the drug throughout the European Union (EU). Hence, introduction of urate-lowering agents is expected to drive the market.
Introduction of biologics to treat gout and increasing adoption of newer therapies further help propel the industry. For instance, in March 2013, Novartis received an EU approval for the product, Ilaris, for use in the treatment of patients suffering from gouty arthritis.
Nonsteroidal Anti-inflammatory Agents (NSAIDs) accounted for the highest share of the market in 2015, which can be credited to highest penetration, higher demand due to low cost, and efficient pain relief.
Urate-lowering agents segment is expected to grow at the highest rate over the coming years. Expected entry of various new drugs, increasing adoption of drugs, and growing investment by key players for development of these agents are likely to drive the segment.
- Takeda Pharmaceutical Company Ltd.
- Savient Pharmaceuticals
- Regeneron Pharmaceuticals
- AstraZeneca plc
- Horizon Pharma plc
- Boehringer Ingelheim
- Merck & Co. Inc
- Teijin Pharma Ltd
Key Topics Covered:
1 Research Methodology
2 Executive Summary
3 Gout Therapeutics Market Variables, Trends & Scope
4 Gout Therapeutics: Drug Class Estimates & Trend Analysis
5 Gout Therapeutics: Disease Condition Estimates & Trend Analysis
6 Gout Therapeutics: Regional Estimates & Trend Analysis
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/nxrjkv/gout_therapeutics